Based on the results of the phase III IMpower150 study comparing atezolizumab plus bevacizumab plus carboplatin and paclitaxel (ABCP) or atezolizumab plus carboplatin and paclitaxel (ACP) to bevacizumab plus carboplatin and paclitaxel (BCP), ABCP has become a standard-of-care regimen and is approved for the first-line treatment of metastatic non-squamous NSCLC without EGFR/ ALK genetic alterations (United States and Europe). Here, ALK is linked to non-small cell lung carcinoma.